Edition:
India

Nabriva Therapeutics PLC (NBRV.OQ)

NBRV.OQ on NASDAQ Stock Exchange Global Select Market

5.10USD
15 Dec 2017
Change (% chg)

$-0.25 (-4.67%)
Prev Close
$5.35
Open
$5.42
Day's High
$5.42
Day's Low
$4.77
Volume
389,331
Avg. Vol
156,949
52-wk High
$14.09
52-wk Low
$4.77

Latest Key Developments (Source: Significant Developments)

Nabriva Therapeutics Announces Completion Of Enrollment In Leap 2, A Phase 3 Clinical Trial Evaluating Oral Lefamulin
Monday, 4 Dec 2017 

Dec 4 (Reuters) - Nabriva Therapeutics Plc ::NABRIVA THERAPEUTICS ANNOUNCES COMPLETION OF ENROLLMENT IN LEAP 2, A PHASE 3 CLINICAL TRIAL EVALUATING ORAL LEFAMULIN FOR THE TREATMENT OF COMMUNITY-ACQUIRED BACTERIAL PNEUMONIA IN ADULTS.NABRIVA THERAPEUTICS PLC - ‍ANTICIPATES TOPLINE CLINICAL RESULTS FROM LEAP 2 TO BE AVAILABLE IN SPRING OF 2018​.  Full Article

Nabriva Therapeutics reports Q3 loss per share $0.79
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Nabriva Therapeutics Plc :Nabriva Therapeutics reports third quarter 2017 financial results and recent corporate highlights.Q3 loss per share $0.79.Q3 earnings per share view $-0.58 -- Thomson Reuters I/B/E/S.Nabriva - On track to complete patient enrollment for second phase 3 trial, leap 2, before year end 2017, & expects topline results in spring 2018​.Nabriva Therapeutics Plc - ‍$112.7 million cash and investments as of September 30, 2017​.Nabriva Therapeutics Plc - ‍Cash balance is expected to fund operations into Q4 of 2018​.  Full Article

Nabriva Q2 loss per share $5.64
Tuesday, 9 Aug 2016 

Nabriva Therapeutics AG: Nabriva reports second quarter 2016 financial results . Q2 loss per share $5.64 .Line data from both cabp phase 3 trials in second half of 2017.  Full Article

Novo A/S reports 5 pct passive stake in Nabriva Therapeutics
Friday, 29 Jul 2016 

Nabriva Therapeutics Ag : Novo A/S reports 5 pct passive stake in Nabriva Therapeutics as of July 19, 2016 - SEC Filing Source - http://bit.ly/2amiXtD Further company coverage: [NBRV.O] (Bengaluru Newsroom; +1 646 223 8780).  Full Article

Nabriva reports Q1 loss per share of $6.41
Tuesday, 10 May 2016 

Nabriva Therapeutics Ag : Do not expect to generate significant revenue unless and until obtain marketing approval for lefamulin . Do not expect to obtain marketing approval for lefamulin before 2018 . Nabriva reports first quarter 2016 financial results .Q1 loss per share $6.41.  Full Article

Nabriva Therapeutics AG appoints Gary Sender as Chief Financial Officer
Monday, 2 May 2016 

Nabriva Therapeutics AG:Says Gary Sender has joined the company as Chief Financial Officer.  Full Article

BRIEF-Nabriva Therapeutics reports Q3 loss per share $0.79

* Nabriva Therapeutics reports third quarter 2017 financial results and recent corporate highlights